{"entity":{"id":"loperamide","kind":"drug","name":"Loperamide","aka":["loperamide hydrochloride"],"tldr":"Loperamide is an anti-diarrhoea capsule. People on some cancer drugs, such as irinotecan and neratinib, are told to keep it at home and start it at the first loose stool.","summary":"The US prescription label covers acute non-specific diarrhoea, chronic diarrhoea of inflammatory bowel disease and reduction of ileostomy output. The irinotecan (Camptosar) label says patients \"should have loperamide readily available to begin treatment for late diarrhea\" and to begin it at the first poorly formed or loose stool. The neratinib (Nerlynx) label, when dose escalation is not used, starts loperamide with the first dose and continues it for the first 56 days, then uses it to keep to one or two bowel movements a day. The Imodium NDA was approved on 28 December 1976.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Loperamide","links":[{"label":"US label (DailyMed): loperamide capsules","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c907d5-87f8-47a6-9544-5a24f5272739"},{"label":"US label (DailyMed): Camptosar (irinotecan), late diarrhoea","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056"},{"label":"US label (DailyMed): Nerlynx (neratinib), diarrhoea prophylaxis","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["irinotecan","neratinib"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Imodium","modality":"Medicine for diarrhoea (peripherally acting opioid receptor agonist, oral)","supportive":true,"mechanism":"Binds opiate receptors in the gut wall, slowing intestinal movement and changing water and electrolyte movement through the bowel (US label).","approvals":[{"region":"US","year":1976,"indication":"Acute non-specific diarrhoea; chronic diarrhoea of inflammatory bowel disease; reducing ileostomy output","note":"Year is the Imodium NDA 017690 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/loperamide/","neighbours":{"drug":[{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/"}],"term":[{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/"}]}}